Navigation Links
TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Date:8/27/2007

new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer's disease. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the anticipated timing for reporting clinical trial results for tezampanel, the potential for tezampanel as a treatment for migraine and other pain indications and the potential of TorreyPines Therapeutics' product candidates to treat certain diseases and disorders. Such statements are subject to numerous factors, risks, and uncertainties that may cause actual events or results to differ materially from the combined company's current expectations. Statements regarding TorreyPines Therapeutics' product candidates are subject to risks and uncertainties regarding development, regulatory approval and commercialization, including whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support an NDA filing, will be approved by the FDA or its equivalent, or if approved, will prove competitive in the market; or whether the necessary financing to support its drug development programs will be available. Actual results may differ materi
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Does your doctor know what ... doctors have recommended marijuana to the over 112,000 currently registered ... the majority of the other roughly 20,300+ active physicians listed ... little about it – even though a poll in February ... say they have tried it. "With marijuana ...
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
(Date:8/29/2014)... According to the new ... (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, ... Synthesis, NGS, DNA, RNAi) - Global Forecast to ... Market is expected to reach $1,712.1 Million by ... a CAGR of 9.8% from 2014 to 2019.. ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... Spherix Incorporated (NASDAQ: SPEX ) -- an ... and atherosclerosis, and providers of technical and regulatory consulting ... today announced that Dr. Claire Kruger, Chief Executive Officer, ... corporate overview at the Rodman & Renshaw 13th Annual ...
... ® Technologies, Inc., a world leader in personal and ... receive the coveted Orange Innovation Award in the 10th annual ... innovative approach to the design, development and manufacture of ... Sudden Cardiac Arrest . The Orange Innovation ...
Cached Medicine Technology:Spherix Incorporated to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 2HeartSine® Technologies Named One of the Most Innovative Businesses in the United Kingdom 2
(Date:8/30/2014)... 2014 According to Bloomberg , ... requires Takeda Pharmaceutical Co. and Eli Lilly & Co. ... that the drugmakers concealed information about a risk of ... case, Allen v. Takeda Pharmaceuticals North America Inc. (12-cv-00064), ... of Louisiana (Lafayette).* , According to Bloomberg, Takeda and ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 ... a Spa-on-Wheels which offers the complete spa experience ... inviting lighting and the most important ingredient of ... "the dedicated licensed pro's! People will enjoy the ... continues Kaplan-Pelle. The website reads, "Step into the ...
(Date:8/30/2014)... Plains, NJ (PRWEB) August 30, 2014 ... first facilities in New Jersey and even in the ... technology that takes inches off of patients’ waists with ... freezing cells in small sections, Vanquish is more inclusive ... pain. Patients lay comfortably under panels about one ...
(Date:8/30/2014)... Jackson, Tenn. (PRWEB) August 30, 2014 ... people around the country for the past several ... the Tennessee Hyperbaric Center have announced a scholarship ... PTSD. This announcement follows a meeting held this ... , In recent years, reporters have shed light ...
(Date:8/30/2014)... Insomnia causes disturbances in every aspect of life. ... developed insomnia and the steps often used to return back ... to the show at this link: Dr. Carol Francis ... 30, and will be podcasted at this link (Click ... DrCarolFrancisTalkRadio.com. , "Insomnia causes countless unrecognized complications. Weight ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Decision to Uphold $9 Billion Actos Award 2Health News:Hands On Mobile Massage and Spa of Long Island Now Offers a Spa-on-wheels 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2
... and Mehmet Oz, MD, Launch Daily Syndicated ... Newspaper Column, ... E? Who better to keep the health momentum going than the YOU ... expert for The Oprah Winfrey Show. King Features Syndicate and,RealAge.com announce the ...
... Texas University of Texas Medical Branch at Galveston ... weapon against respiratory syncytial virus, the most common cause ... an effort to find an effective antiviral therapy for ... molecule to interfere with the genetic machinery that RSV ...
... Response Essentially Met but Donations Still Needed to Prepare,for ... WASHINGTON, May 5 The American Red Cross,today ... the Southeastern,Virginia tornadoes but donations to its Disaster Relief ... the next disaster, particularly with the,beginning of hurricane season ...
... Exclusive License for Pulse!! Virtual Learning Platform for ... Clinical Skills and Decision Making Training, ... developer of,game-based technology solutions for training, experimentation and,decision-making analysis, ... System for the exclusive, worldwide rights to Pulse!! the,Virtual ...
... Herley Industries, Inc.,(Nasdaq: HRLY ) announced today ... U.S. Government on all existing criminal and civil,claims. These ... had been scheduled for trial on May 5, 2008 ... control oscillators in January 2001 and,two contracts involving the ...
... a previously unrealized mechanism by which the epidermal growth ... cancer cells through a kinase-independent mechanism. The research, published ... journal Cancer Cell, provides a rationale for the less ... at interfering with kinase activity and suggests new directions ...
Cached Medicine News:Health News:Need a Daily Dose of Good Health Advice to Keep You Going? 2Health News:Need a Daily Dose of Good Health Advice to Keep You Going? 3Health News:New agent strikes at respiratory syncytial virus replication 2Health News:Generous Donors Allow Red Cross to Respond Swiftly and Effectively to Southeastern Virginia Tornadoes 2Health News:Generous Donors Allow Red Cross to Respond Swiftly and Effectively to Southeastern Virginia Tornadoes 3Health News:Game-Based Technology to Meet Demand for Improved Medical Teaching and Training 2Health News:Game-Based Technology to Meet Demand for Improved Medical Teaching and Training 3Health News:Herley Announces Settlement Agreement with U.S. Government 2Health News:Herley Announces Settlement Agreement with U.S. Government 3Health News:EGFR protects cancer cells from starvation via a kinase-independent mechanism 2
... WideBiter Punch series facilitates fast and effective ... smooth, anatomically shaped meniscal rim. The flat, ... to access even the tightest joint spaces. ... Inc., 20 years of engineering experience in ...
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
... series facilitates fast and effective resection of ... shaped meniscal rim. The flat, crescent-shaped tip ... even the tightest joint spaces. Made in ... years of engineering experience in arthroscopy hand ...
... facilitates fast and effective resection of meniscal ... meniscal rim. The flat, crescent-shaped tip has ... the tightest joint spaces. Made in the ... of engineering experience in arthroscopy hand instrument ...
Medicine Products: